歯周病治療薬の市場規模、シェア、動向分析レポート：疾患別、薬物タイプ別、流通チャネル別、地域別、セグメント予測、2024年～2030年

歯周病治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の歯周病治療薬市場規模は2030年までに14億1,000万米ドルに達し、2024年から2030年までのCAGRは7.2%で成長すると予測されています。

この市場を牽引しているのは、主に高齢者人口の増加に伴う歯周病有病率の増加です。NCBIが2023年9月に発表した記事によると、この病気に罹患する高齢者の割合は2020年の42.44%から2050年には54.57%に上昇すると予測されています。軽度の歯周病が引き続き最も多く、80.39%を占めると予測されています。さらに、治療されていない虫歯の数は、2020年から2050年の間に75.2%増加すると予測されています。

口腔の健康に対する意識の高まりが市場の成長を後押ししています。様々な集団における歯の健康状態の悪化という広範な問題に焦点を当て、形成的ニーズ調査から得られたデータを用いて数多くのキャンペーンが作成されてきました。これらのイニシアチブは、歯周保健に対する認識と知識を高め、セルフケアによる歯科予防行動を促進し、歯科保健サービスの利用を促すことを目的としています。一部のキャンペーンは、成人、小児、乳幼児の親、歯の問題のリスクが高いと考えられる社会経済的に恵まれないグループなど、特定の層に合わせたものでした。ノルウェーのペリオ・イヤーキャンペーンは、15歳以上の個人を対象とし、意識向上を図った。このキャンペーンの一環として、歯科医師は1年間の研修を受け、患者の診察時にキャンペーンのメッセージを強化しました。このキャンペーンは、多様なメディアチャンネルを活用し、食料品店、薬局、歯科医院に情報冊子を配布しました。

歯周病に関連する抗生物質耐性菌の出現は、いくつかの重要な行動と配慮を必要とします。例えば、2022年10月、歯周病に関連する微生物における抗菌薬耐性の評価に焦点を当てた調査研究は、これらの細菌における耐性の範囲を理解するための継続的な研究の重要性を強調しています。この調査は、抗菌薬耐性に効果的に対処するための標的治療と戦略を開発する必要性を強調しています。この調査は、抗菌薬の無差別処方による抗菌薬耐性へのヘルスケア専門家の有害な影響を強調しています。このことは、適切な処方を遵守することの重要性と、医療従事者が、自分が対処している細菌の耐性パターンに関する認識を持つ必要性を強調しています。

さらに、医薬品開発における技術的進歩は、ビッグデータマイニング、システム生物学、ディープラーニング手法の統合によって大きな影響を受けています。これらの進歩は、歯肉や歯周組織における炎症や感染を特徴とする疾患の治療のための新規薬剤の発見と開発を強化することを目的としています。重要な手法のひとつは、中等度から重度の歯周炎患者のデータを含むGSE10334データセットのような、ゲノムワイドなマイクロアレイデータセットの解析にビッグデータマイニングを活用することです。このアプローチにより、疾患プロセスに関与する候補遺伝子、タンパク質間相互作用（PPIN）ネットワーク、および制御ネットワーク（GRN）の同定が可能になります。システム同定およびシステム次数検出法を適用することにより、研究者は、疾患群と健常対照群の両方について、真の遺伝子ワイド遺伝子発現ネットワーク（GWGEN）をピンポイントで特定することができます。このステップは、疾患の根底にある分子メカニズムを解明し、薬剤開発の潜在的標的を特定するために極めて重要です。

歯周病治療薬市場レポートハイライト

• 2023年には、慢性歯周病セグメントが市場で最大のシェアを占めました。これは、患者の不快感が大きいため治療率が高いこと、治療アドヒアランス率が高いこと、そして全体的に有病率が高まっていることに起因しています。
• 2023年には、ドキシサイクリン系薬剤が市場を独占しました。ドキシサイクリンは、低濃度でも歯周炎に多く含まれる酵素であるマトリックスメタロプロテアーゼ-8（MMP-8）を阻害することが判明しています。
• 病院薬局の流通チャネルが2023年の市場で最大のシェアを占めました。病院での処方率の高さ、病院薬局で処方された薬を購入する患者の嗜好性の高さ、歯周病で病院を訪れる患者の増加がこのセグメントの成長を牽引しています。
• 北米は、高度なヘルスケアインフラ、疾患の有病率の上昇、良好な規制環境などの要因により、市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 歯周病治療薬市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 歯周病治療薬市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • 価格分析

第4章 歯周病治療薬市場：疾患の推定・動向分析

• 世界の歯周病治療薬市場：疾患別ダッシュボード
• 世界の歯周病治療薬市場：疾患別変動分析
• 世界の歯周病治療薬市場：疾患別、収益別
• 歯肉炎
• 慢性歯周病
• 進行性歯周病
• その他

第5章 歯周病治療薬市場：薬剤タイプの推定・動向分析

• 世界の歯周病治療薬市場：薬剤タイプ別ダッシュボード
• 世界の歯周病治療薬市場：薬剤タイプ別変動分析
• 世界の歯周病治療薬市場：薬剤タイプ別、収益別
• ドキシサイクリン
• ミノサイクリン
• クロルヘキシジン
• メトロニダゾール
• その他

第6章 歯周病治療薬市場：流通チャネルの推定・動向分析

• 世界の歯周病治療薬市場：流通チャネル別ダッシュボード
• 世界の歯周病治療薬市場：流通チャネル別変動分析
• 世界の歯周病治療薬市場：流通チャネル別、収益別
• 病院薬局
• 小売薬局
• オンラインチャンネル

第7章 歯周病治療薬市場：疾患、薬剤タイプ、流通チャネル別の地域推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年から2030年：
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主なディストリビューターとチャネルパートナーのリスト
  • 主要顧客
  • 主要市場の企業シェア分析, 2023年
  • Pfizer Inc.
  • Lupin Ltd
  • Teva Pharmaceuticals USA, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Tokyo Chemical Industry Co., Ltd.
  • Bausch Health Companies Inc.
  • USAntibiotics
  • Melinta Therapeutics LLC
  • Cipla, Inc.
  • Chartwell Pharmaceuticals LLC.

List of Tables

• Table 1 List of abbreviations
• Table 2 North America periodontal therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 3 North America periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 4 North America periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 5 North America periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 6 U.S. periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 7 U.S. periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 8 U.S. periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 9 Canada periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 10 Canada periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 11 Canada periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 12 Europe periodontal therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 13 Europe periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 14 Europe periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 15 Europe periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 16 Germany periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 17 Germany periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 18 Germany periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 19 UK periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 20 UK periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 21 UK periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 22 France periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 23 France periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 24 France periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 25 Italy periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 26 Italy periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 27 Italy periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 28 Spain periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 29 Spain periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 30 Spain periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 31 Denmark periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 32 Denmark periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 33 Denmark periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 34 Sweden periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 35 Sweden periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 36 Sweden periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 37 Norway periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 38 Norway periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 39 Norway periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific periodontal therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 44 China periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 45 China periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 46 China periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 47 Japan periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 48 Japan periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 49 Japan periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 50 India periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 51 India periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 52 India periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 53 South Korea periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 54 South Korea periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 55 South Korea periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 56 Australia periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 57 Australia periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 58 Australia periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 59 Thailand periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 60 Thailand periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 61 Thailand periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 62 Latin America periodontal therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 63 Latin America periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 64 Latin America periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 65 Latin America periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 66 Brazil periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 67 Brazil periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 68 Brazil periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 69 Mexico periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 70 Mexico periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 71 Mexico periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 72 Argentina periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 73 Argentina periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 74 Argentina periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 75 MEA periodontal therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 76 MEA periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 77 MEA periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 78 MEA periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 79 South Africa periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 80 South Africa periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 81 South Africa periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 85 UAE periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 86 UAE periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 87 UAE periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 88 Kuwait periodontal therapeutics market, by Disease, 2018 - 2030 (USD Million)
• Table 89 Kuwait periodontal therapeutics market, by drug type, 2018 - 2030 (USD Million)
• Table 90 Kuwait periodontal therapeutics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 periodontal therapeutics market: market outlook
• Fig. 14 Periodontal Therapeutics competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 periodontal therapeutics market driver impact
• Fig. 18 periodontal therapeutics market restraint impact
• Fig. 19 periodontal therapeutics market: Disease movement analysis
• Fig. 20 periodontal therapeutics market: Disease outlook and key takeaways
• Fig. 21 Gingivitis market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Chronic Periodontal Disease market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Aggressive Periodontal Disease market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 periodontal therapeutics market: Drug Type movement analysis
• Fig. 26 periodontal therapeutics market: Drug Type outlook and key takeaways
• Fig. 27 Doxycycline market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Minocycline market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Chlorhexidine market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Metronidazole market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Other drug types market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 periodontal therapeutics market: Distribution Channel movement analysis
• Fig. 33 periodontal therapeutics market: Distribution Channel outlook and key takeaways
• Fig. 34 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Retail Pharmacies estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Online Channel market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Global periodontal therapeutics market: Regional movement analysis
• Fig. 38 Global periodontal therapeutics market: Regional outlook and key takeaways
• Fig. 39 Global periodontal therapeutics market share and leading players
• Fig. 40 North America, by country
• Fig. 41 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 U.S. key country dynamics
• Fig. 43 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Canada key country dynamics
• Fig. 45 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 UK key country dynamics
• Fig. 48 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Germany key country dynamics
• Fig. 50 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 France key country dynamics
• Fig. 52 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Italy key country dynamics
• Fig. 54 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Spain key country dynamics
• Fig. 56 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Denmark key country dynamics
• Fig. 58 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Sweden key country dynamics
• Fig. 60 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Norway key country dynamics
• Fig. 62 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 China key country dynamics
• Fig. 65 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Japan key country dynamics
• Fig. 67 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 India key country dynamics
• Fig. 69 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Thailand key country dynamics
• Fig. 71 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 South Korea key country dynamics
• Fig. 73 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Australia key country dynamics
• Fig. 75 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Brazil key country dynamics
• Fig. 78 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Mexico key country dynamics
• Fig. 80 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Argentina key country dynamics
• Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 South Africa key country dynamics
• Fig. 85 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Saudi Arabia key country dynamics
• Fig. 87 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 UAE key country dynamics
• Fig. 89 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Kuwait key country dynamics
• Fig. 91 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Market share of key market players - periodontal therapeutics market

Periodontal Therapeutics Market Growth & Trends:

The global periodontal therapeutics market size is anticipated to reach USD 1.41 billion by 2030, growing at a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of periodontal diseases aided by the growing geriatric population. According to an article published by NCBI, in September 2023, the percentage of older adults affected by the disease is anticipated to rise from 42.44% in 2020 to 54.57% by 2050. Mild periodontal diseases are predicted to continue being the most common type, accounting for 80.39% of cases. Additionally, the number of untreated cavities in teeth is expected to increase by 75.2% between 2020 and 2050.

Increasing awareness about oral health fuels the growth of the market. Numerous campaigns have been created using data from formative needs assessments, focusing on the widespread issue of poor dental health in various populations. These initiatives aimed to increase awareness and knowledge about periodontal health, promote self-care dental preventive behaviors, and encourage the utilization of dental health services. Certain campaigns were tailored to specific demographics, including adults, children, parents of infants, and disadvantaged socio-economic groups considered to be at higher risk for dental problems. The Perio-Year Campaign in Norway targeted individuals aged 15 and above to increase awareness. As part of the initiative, dentists received one year of training to reinforce campaign messages during patient consultations. The campaign utilized diverse media channels and distributed informational booklets to grocery stores, pharmacies, and dental offices.

The emergence of antibiotic-resistant strains of bacteria associated with periodontal diseases necessitates several key actions and considerations. For instance, in October 2022, a research study focused on assessing antimicrobial resistance in microorganisms associated with periodontal diseases underscores the importance of ongoing research in understanding the scope of resistance among these bacteria. This investigation highlights the necessity for developing targeted treatments and strategies to address antibiotic resistance effectively.The study emphasizes the detrimental impact of healthcare professionals on antimicrobial resistance due to indiscriminate prescribing of antimicrobials. This emphasizes the significance of adhering to appropriate prescribing practices and the necessity for healthcare providers to possess awareness regarding the resistance patterns of the bacteria they are addressing.

Furthermore, technological advancements in drug development have been significantly influenced by the integration of big data mining, systems biology, and deep learning methods. These advancements aim to enhance the discovery and development of novel drugs for the treatment of the diseases, which are characterized by inflammation and infection in the gums and periodontal tissues. One key methodology involves leveraging big data mining to analyze genome-wide microarray datasets, such as the GSE10334 dataset, which contains data from individuals with moderate to severe periodontitis. This approach enables the identification of candidate genes, protein-protein interaction (PPIN) networks, and regulatory networks (GRNs) involved in the disease process. Applying system identification and system order detection methods, researchers can pinpoint genuine gene-wide gene expression networks (GWGENs) for both diseased and healthy control groups. This step is crucial for elucidating the molecular mechanisms underlying the disease and identifying potential targets for drug development.

Periodontal Therapeutics Market Report Highlights:

• The chronic periodontal disease segment held the largest share of the market in 2023. It can be attributed to the high treatment rate of the disease due to significant discomfort to the patients, high treatment adherence rate, and overall, a growing prevalence of the disease.
• The doxycycline drug type dominated the market in 2023. Doxycycline, even at lower concentrations, has been found to inhibit matrix metalloproteinase-8 (MMP-8), an enzyme abundant in periodontitis.
• Hospital pharmacies distribution channel held the largest share of the market in 2023. The high prescription rates at hospitals, high patient preference of purchase prescribed medications from hospital pharmacies, and increasing number of patients visiting hospitals for periodontal diseases are driving the growth of this segment.
• North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of the disease, and favorable regulatory environment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease
  • 1.2.2. Drug Type
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease and Drug Type outlook
  • 2.2.2. Distribution Channel outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Periodontal Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing prevalence of periodontal diseases
    • 3.2.1.2. Increasing awareness about oral health
    • 3.2.1.3. Rising geriatric population
    • 3.2.1.4. Technological advancements in dentistry
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited awareness and education for oral health
    • 3.2.2.2. Stringent regulatory policies
• 3.3. Periodontal Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis

Chapter 4. Periodontal Therapeutics Market: Disease Estimates & Trend Analysis

• 4.1. Global Periodontal Therapeutics Market: Disease Dashboard
• 4.2. Global Periodontal Therapeutics Market: Disease Movement Analysis
• 4.3. Global Periodontal Therapeutics Market by Disease, Revenue
• 4.4. Gingivitis
  • 4.4.1. Gingivitis market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Chronic Periodontal Disease
  • 4.5.1. Chronic Periodontal Disease market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Aggressive Periodontal Disease
  • 4.6.1. Aggressive Periodontal Disease market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Periodontal Therapeutics Market: Drug Type Estimates & Trend Analysis

• 5.1. Global Periodontal Therapeutics Market: Drug Type Dashboard
• 5.2. Global Periodontal Therapeutics Market: Drug Type Movement Analysis
• 5.3. Global Periodontal Therapeutics Market by Drug Type, Revenue
• 5.4. Doxycycline
  • 5.4.1. Doxycycline market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Minocycline
  • 5.5.1. Minocycline market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Chlorhexidine
  • 5.6.1. Chlorhexidine market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Metronidazole
  • 5.7.1. Metronidazole market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Other drug types
  • 5.8.1. Other drug types market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Periodontal Therapeutics Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global Periodontal Therapeutics Market: Distribution Channel Dashboard
• 6.2. Global Periodontal Therapeutics Market: Distribution Channel Movement Analysis
• 6.3. Global Periodontal Therapeutics Market by Distribution Channel, Revenue
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Online Channel
  • 6.6.1. Online Channel market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Periodontal Therapeutics Market: Regional Estimates & Trend Analysis by Disease, Drug Type, and Distribution Channel

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Pfizer Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Lupin Ltd
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Teva Pharmaceuticals USA, Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Sun Pharmaceutical Industries Ltd.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Tokyo Chemical Industry Co., Ltd.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Bausch Health Companies Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. USAntibiotics
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Melinta Therapeutics LLC
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Cipla, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Chartwell Pharmaceuticals LLC.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. benchmarking
    • 8.3.13.4. Strategic initiatives